Table 2 Subsequent anti-HCC treatment among patients having received lenvatinib or sorafenib as first systemic treatment
| Â | Lenvatinib (15/44, 34.1%) | Sorafenib (46/88, 52.3%) | p-value 0.048 |
|---|---|---|---|
Systemic treatment | 12 (80.0%) | 43 (93.5%) | Â |
  Sorafenib | 9 (75.0%) | 0 (0.0%) |  |
  Regorafenib | 0 (0.0%) | 34 (79.1%) |  |
  Nivolumab | 0 (0.0%) | 6 (14.0%) |  |
  Dendritic cell immunotherapy | 1 (8.3%) | 0 (0.0%) |  |
  Others | 2 (16.7%) | 3 (7.0%) |  |
Locoregional treatment only | 3 (20.0%) | 3 (6.5%) | Â |